Collectively, these interactions highlight the intricate involvement of CD133 in multiple molecular pathways and signaling networks that regulate CSC properties and tumor progression, offering potential therapeutic targets for disrupting CSC-mediated tumor growth and therapy resistance. This evidence concerns the gene PROM1 and neoplasm.